Skip to main content

Glossary

B

belimumab (benlysta)

Benlysta is a human monoclonal antibody that was approved for the treatment of lupus by the U.S. Food and Drug Administration (FDA) on March 9, 2011 and for lupus nephritis on December 17, 2020. Benlysta was also approved by the FDA to treat lupus in children and teens (5 to 17) in 2019 and for treatment of lupus nephritis in the age group in 2022. A monoclonal antibody is a type of protein made in the laboratory that is developed to find and attach to only one type of substance in the body. For more information, visit What You Need to Know About Benlysta.


Glossary Sources

1 NIH.gov
2 Merriam-Webster Dictionary
3 Medline Plus
4 Mayo Clinic
5 CMS.gov